New golden standard for medicine safety during breastfeeding

(Press-News.org) Women who choose to stop treatment during pregnancy and breastfeeding are putting their health at risk, and have to weigh their desire to have children and breastfeed against a risk that we know very little about. In two ongoing clinical trials, researchers establish a new standard for human lactation studies that includes sampling of breast milk and plasma from both mothers  and breastfed infants. 

“The lack of scientific evidence is an ethical problem for women and doctors, considering that around 70 percent of women need to use medicines sometime during their pregnancy. In many cases, women are recommended to refrain from breastfeeding or stop using their medicines. However, breastfeeding has benefits for both mother and child,” says Mats G. Hansson, senior professor of biomedical ethics, Uppsala University’s Centre for Research Ethics & Bioethics, head of two ongoing clinical trials.

95 percent of all medicines have not been studied well enough to include safety information for pregnancy and breastfeeding on the label. The current standard for lactation studies uses animal data and concentrations of medicines in mother’s milk, using PB/PK to estimate how much of a particular substance transfers to the baby. The studies that exist are old and rely on data from very few individuals, with old analysis methods. 

BMJ Open has just published a protocol for a new golden standard for clinical lactation studies, looking at the concentration of prednisolone in the mother’s milk, and plasma from both mother and infant. Prednisolone is prescribed for several conditions, including Rheumatoid Arthritis, a chronic and debilitating condition that requires long-term treatment. 

Samples are biobanked and analysed with regard to pharmacokinetic properties of the medicines and transfer from breast milk to infant plasma. The present studies are focusing on prednisolone, used in the treatment of Rheumatoid Arthritis, and metformin, used in the treatment of type 2 Diabetes. With biobanking and the obtainment of informed consent for future, yet unspecified research, the protocol opens for long-term follow up of medication effects on breastfeeding infants. 

Women are recruited through a network of clinical centres in Sweden, and the samples are stored for future research in a network of breast milk biobanks managed by BBMRI-ERIC. According to Mats G. Hansson, this ensures the study is part of a larger European infrastructure, making future research possible. 

The just-published protocol was developed within the large European collaboration framework ConcePTION, and describes how samples are collected and analysed. 

END